<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112498</url>
  </required_header>
  <id_info>
    <org_study_id>CA224-087</org_study_id>
    <nct_id>NCT04112498</nct_id>
  </id_info>
  <brief_title>A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab</brief_title>
  <official_title>A Phase 1, Multi-Tumor, Bioavailability Study of Relatlimab in Combination With Nivolumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will characterize the movement of drugs within the body, evaluate safety and
      determine to which extent the body can process relatlimab in combination with nivolumab in
      subjects with certain advanced tumors
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">August 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 18, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum observed serum concentration (Cmax)</measure>
    <time_frame>approximately 60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>approximately 60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the time-concentration curve over the dosing interval AUC (TAU)</measure>
    <time_frame>approximately 60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed concentration at the end of the dosing interval (Ctau)</measure>
    <time_frame>approximately 60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events leading to discontinuation</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of deaths</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of laboratory abnormalities</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverese Events (AEs) in the broad SMQ of Anaphylactic Reaction</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of events within the hypersensitivity/infusion reaction select AE category</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-relatlimab antibodies and neutralizing antibodies (if applicable)</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-nivolumab antibodies and neutralizing antibodies (if applicable)</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>nivolumab + relatlimab + rHuPH20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>relatlimab</intervention_name>
    <description>Specified dose on Specified days</description>
    <arm_group_label>nivolumab + relatlimab + rHuPH20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>Specified dose on Specified days</description>
    <arm_group_label>nivolumab + relatlimab + rHuPH20</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHuPH20</intervention_name>
    <description>Specified dose on Specified days</description>
    <arm_group_label>nivolumab + relatlimab + rHuPH20</arm_group_label>
    <other_name>Enhanze</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histologic or cytologic confirmation of (unresectable and/or metastatic) advanced
             solid tumors

          -  Melanoma

          -  Metastatic squamous or non- squamous non-small cell lung cancer (NSCLC)

          -  Gastric adenocarcinoma (includes gastro-esophageal junction)

          -  Hepatocellular carcinoma (HCC)

          -  Squamous cell carcinoma of the head and neck (SCCHN)

          -  Renal cell carcinoma (RCC)

          -  Bladder cancer

          -  Participants must have received available standard therapies

          -  Women and men must agree to follow instructions for method of contraception

          -  Measureable disease as per RECIST version 1.1 criteria

          -  Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status
             of 0 or 1

        Exclusion Criteria:

          -  Participants must not have active brain metastases or leptomeningeal metastases

          -  Participants with HCC must not have any history of hepatic encephalopathy, any prior
             (within 1 year) or current clinically significant ascites

          -  History of allergy or hypersensitivity to study drug components

          -  Participants with serious or uncontrolled cardiovascular disease

          -  Excluding patients with serious or uncontrolled medical disorders

          -  Participants with a condition requiring systemic treatment with either corticosteroids
             (&gt; 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
             days of start of study treatment

          -  Participants with an active, known, or suspected autoimmune disease

          -  Participants must not have evidence of organ dysfunction or any clinically significant
             deviation from normal in physical examination, vital signs, ECG or clinical laboratory
             determinations beyond what is consistent with the target population

        Other protocol defined inclusion/exclusion Criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601-1914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

